Though rare, they can include issues with your pancreas or gallbladder, changes in vision, or a rapid heartbeat
Proteolytically stable foldamer mimics of host-defense peptides with protective activities in a murine model of bacterial infection
"Structure-function of the glucagon receptor family of G protein-coupled receptors, coupled to: the glucagon, GIP, GLP-1, and GLP-2 receptors"
Researchers Cited in This Article The researchers below authored or co-authored publications cited in this article
More FAQs about NIOD CAIS So is the mixing version of CAIS no longer going to be available
On the competitive front, Viking Therapeutics plans to advance its oral GLP-1 candidate VK2735 into Phase 3 trials in Q4 2026, while Structure Therapeutics is expected to initiate late-stage studies of aleniglipron in the second half of the year